Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates
Cantley, Richard L.; Wang, Xiaoming; Reichert, Zachery R.; Chinnaiyan, Arul M.; Mannan, Rahul; Cao, Xuhong; Spratt, Daniel E.; Vaishampayan, Ulka N.; Alumkal, Joshi J.; Morgan, Todd M.; Palapattu, Ganesh; Davenport, Matthew S.; Pantanowitz, Liron; Mehra, Rohit
2023-02
Citation
Cantley, Richard L.; Wang, Xiaoming; Reichert, Zachery R.; Chinnaiyan, Arul M.; Mannan, Rahul; Cao, Xuhong; Spratt, Daniel E.; Vaishampayan, Ulka N.; Alumkal, Joshi J.; Morgan, Todd M.; Palapattu, Ganesh; Davenport, Matthew S.; Pantanowitz, Liron; Mehra, Rohit (2023). "Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates." Cancer Cytopathology 131(2): 117-135.
Abstract
IntroductionThe diagnosis of metastatic prostatic cancer (MPC) by fine needle aspiration (FNA) can usually be rendered by typical cytomorphologic and immunohistochemical (IHC) features. However, MPC diagnosis may be complicated by transformation to atypical phenotypes such as small cell carcinoma, typically under pressure from androgen deprivation therapy (ADT). Predictive and prognostic biomarkers can also be assessed by IHC. This study illustrates how careful assessment of cytologic and biomarker features may provide therapeutic and prognostic information in MPC.DesignWe reviewed our anatomic pathology archives for MPC diagnosed by FNA from January 2014 to June 2021. Clinical histories, cytology slides, and cell blocks were reviewed. Extensive IHC biomarker workup was performed, including markers of prostate lineage, cell-cycle dysfunction, Ki-67, neuroendocrine markers, PDL1, and androgen receptor splice variant 7. Cases were reclassified into three categories: conventional type, intermediary type, and high-grade neuroendocrine carcinoma (HGNC).ResultsEighteen patients were identified. Twelve had conventional MPC, including six of six ADT-naive patients. Six of twelve (50%) with prior ADT were reclassified as intermediary or HGNC. Four intermediary cases included two with squamous differentiation and two with pro-proliferative features. Two HGNC cases had typical small cell carcinoma cytomorphology. Expression of PDL1 was�identified in�two cases and ARv7 in three cases. Five of five intermediary and HGNC patients died of disease versus six of eleven with with conventional type.ConclusionsAggressive cytomorphologic variants were commonly identified in patients with prior ADT. Identification of nonconventional cytomorphology and increased proliferation can provide important prognostic information. Recognition of these changes is important for an accurate diagnosis, and the identification of high-grade variants can affect therapeutic decision-making. Clinically actionable biomarkers such as PDL1 and ARv7 can be assessed by IHC.Aggressive cytomorphologic variants of metastatic prostate cancer are common in patients treated with androgen deprivation. Recognition of these changes is important for accurate diagnosis, and identification of high-grade variants can impact therapeutic decision making.Publisher
Wiley Periodicals, Inc. Springer
ISSN
1934-662X 1934-6638
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.